

SEQUENCE LISTING

5 <110> Amersham Health AS

10 <120> Optical imaging contrast agents

15 <130> PN0399

20 <140> NO20035748

 <141> 2003-12-19

25 <160> 2

 <170> PatentIn version 3.1

30 <210> 1

 <211> 5

35 <212> PRT

 <213> Artificial sequence

40 <220>

 <223> Synthetic peptide

45 <400> 1

 Asp Phe Lys Arg Gly
 1 5

50 <210> 2

 <211> 9

55 <212> PRT

 <213> Artificial Sequence

60

<220>

<223> Synthetic peptide

5 <400> 2

Cys Gly Pro Leu Gly Leu Leu Ala Arg
1 5

10

Claims:

1. An optical imaging contrast agent with affinity for an abnormally expressed biological target associated with vulnerable atherosclerotic plaque.

5

2. A contrast agent as claimed in claim 1 with molecular weight below 14 000 Daltons.

3. A contrast agent as claimed in claim 1 or 2 of formula I

10

V-L-R, (I)

wherein V is one or more vector moieties having affinity for an abnormally expressed target in vulnerable atherosclerotic plaque, L is a linker moiety or a bond and R is one or more reporter moieties detectable in optical imaging.

15

4. A contrast agent as claimed in any of claims 1 to 3 comprising a contrast agent substrate, wherein the target is an abnormally expressed enzyme, such that the contrast agent changes pharmacodynamic properties and/or pharmacokinetic properties upon a chemical modification from a contrast agent substrate to a contrast agent product upon a specific enzymatic transformation.

20

5. A contrast agent as claimed in any of claims 1 to 4 having affinity for any of the targets selected from kistrin, collagens, cathepsin B, cathepsin K, matrix metalloproteinase 3, matrix metalloproteinase 9, myeloperoxidase, urokinase, endothelin, CCR-2, C-reactive protein, angiotensin II receptors, CD36, CD40, folate receptor, SR-A, SR-B1, Toll-like receptor 4, uPAR, VEGF receptor, LOX-1, PPAR- γ , Factor XIII, HBP/Vigilin, perilipin.

25

6. A contrast agent as claimed in any of claims 3 to 5 wherein V is selected from peptides, peptoid moieties, oligonucleotides, oligosaccharides, fat-related compounds, and traditional organic drug-like small molecules.

30

7. A contrast agent as claimed in any of claims 3-6 wherein R is a dye that interacts with light in the wavelength region from the ultraviolet to the near-infrared part of the electromagnetic spectrum.

35

8. A pharmaceutical composition for optical imaging of vulnerable atherosclerotic plaque comprising a contrast agent as defined in any of claims 1 to 7 together with at least one pharmaceutically acceptable carrier or excipient.

5 9. Use of a contrast agent as claimed in any of claims 1 to 7 for the manufacture of a diagnostic agent for use in a method of optical imaging of vulnerable atherosclerotic plaque involving administration of said diagnostic agent to an animate subject and generation of an image of at least part of said subject.

10 10. A method of optical imaging of vulnerable atherosclerotic plaque of an animate subject involving administering a contrast agent as defined in any of claims 1 to 7 to the subject and generating an optical image of at least a part of the subject to which said contrast agent has distributed.

15 11. Method as claimed in claim 10 for diagnosis of vulnerable atherosclerotic plaque, for follow up of the progress of vulnerable atherosclerotic plaque development, for follow up of treatment of vulnerable atherosclerotic plaque or for surgical guidance.

20 12. Use of a contrast agent as defined in any of claim 1 to 7 for optical imaging of vulnerable atherosclerotic plaque.

25 13. Use of a contrast agent as claimed in claim 12 for diagnosis of vulnerable atherosclerotic plaque, for follow up of the progress of vulnerable atherosclerotic plaque development, for follow up of treatment of vulnerable atherosclerotic plaque or for surgical guidance.